Search Results
Your search for early matches 10016 pages
Showing 3151 - 3200Novel Treatment Approaches on the Horizon in Multiple Myeloma
Clinicians who treat multiple myeloma can anticipate a host of new treatments: melflufen, cereblon E3 ligase modulators (CELMoDs), antibody-drug conjugates, bispecific antibodies, and chimeric antigen receptor (CAR) T-cell therapies. Kenneth C. Anderson, MD, FASCO, Director of the Jerome Lipper...
Hematologic Oncology Highlights 2019–2020 Almanac
The past year has seen remarkable advances in the treatment of leukemia, lymphoma, and multiple myeloma, which combined account for 9.9% of the estimated 1,806,590 new cases of cancer diagnosed in the United States and an estimated 56,840 cancer-related deaths.1 Novel therapies are providing...
Guideline Update Offers New Directions About Trastuzumab Emtansine for HER2-Positive Breast Cancer
About 10% to 20% of newly diagnosed breast cancers demonstrate overexpression of the HER2 protein.1 Since the introduction of trastuzumab, several new HER2-targeted therapies have been approved for use in the adjuvant and metastatic settings (eg, pertuzumab, lapatinib, and neratinib). However, for...
Study Finds Medicaid Expansion in Louisiana Increased Early-Stage Breast Cancer Diagnosis and Access to Treatment
A study by Quyen D. Chu, MD, MBA, FACS, and colleagues published in the journal Cancer investigated how expansion of the Medicaid provision in the the Patient Protection and Affordable Care Act (ACA) affected breast cancer care in Louisiana. The state is the third poorest in the country and has one ...
Bispecific Antibodies Poised to Impact Treatment of Lymphoma and Other Blood Cancers
Studies of second-generation bispecific antibodies were among the highlights of the 2019 American Society of Hematology (ASH) Annual Meeting & Exposition. The bispecific T-cell engager blinatumomab was the first such agent to be approved by the U.S. Food and Drug Administration (FDA) in...
Newer Therapeutic Approaches Improving Outcomes in Hodgkin Lymphoma
At the 2020 Debates and didactics in Hematology and Oncology Virtual Conference, sponsored by Emory University School of Medicine and Winship Cancer Institute, Pamela Allen, MD, Assistant Professor of Medicine at Emory, described recent trials on therapeutic approaches that are informative on this ...
Optimizing the Treatment of Adults With Acute Lymphoblastic Leukemia
In the treatment of adults with acute lymphoblastic leukemia (ALL), use of newer antibodies and de-intensification of chemotherapy have greatly improved outcomes, according to Hagop Kantarjian, MD, FASCO, who has been very involved in much of the research in ALL treatment. Dr. Kantarjian, Professor ...
Screening Younger Women for Variants Linked to Breast and Ovarian Cancers May Be Cost-Effective
Population-wide screening for genetic variants linked to hereditary breast and ovarian cancers may be cost-effective in women between the ages of 20 and 35, according to a study published by Guzauskas et al in JAMA Network Open. However, screening for older women was not cost-effective, the...
State of Lung Cancer Report Finds People of Color Face Greater Burden, Worse Lung Cancer Outcomes in the United States
People of color diagnosed with lung cancer face worse outcomes compared to White Americans, according to the American Lung Association’s third annual State of Lung Cancer report. The 2020 State of Lung Cancer report tracks the toll of lung cancer by state, and for the first time, this year’s report ...
Researchers Develop Prognostic Model to Guide Systemic Therapy for Early-Stage HER2-Positive Breast Cancer
As reported in The Lancet Oncology, Prat et al have developed a prognostic risk score model—HER2DX—that can be used to identify patients with early-stage HER2-positive breast cancer who might be candidates for escalated or de-escalated systemic treatment. As stated by the investigators, “In...
Study Finds the Lung Microbiome May Affect Tumor Progression and Prognosis in Patients With Lung Cancer
A new study by Tsay et al sheds light on the role the lung microbiome may play in lung cancer pathogenesis and prognosis. According to the study’s findings, enrichment of the lungs with oral commensal microbes was associated with advanced-stage disease, worse prognosis, and tumor progression....
Paclitaxel Plus Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer: Long-Term Follow-up and Genomic Analysis
In a 7-year follow-up of the phase III CALGB 40601/Alliance neoadjuvant trial reported in the Journal of Clinical Oncology, Fernandez-Martinez et al found that paclitaxel combined with trastuzumab/lapatinib was associated with improved survival outcomes vs paclitaxel/trastuzumab in women with...
Virtual Mind-Body Services for Patients With Cancer During the COVID-19 Pandemic
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. In this installment, Jun J. Mao, MD, MSCE, and Jyothirmai Gubili, MS, focus on the role of virtual...
Adjuvant Irinotecan/Cisplatin vs Etoposide/Cisplatin for Resected High-Grade Neuroendocrine Carcinoma of the Lung
In a Japanese phase III trial reported in the Journal of Clinical Oncology, Kenmotsu et al found that adjuvant irinotecan/cisplatin did not improve relapse-free survival vs etoposide/cisplatin in patients with completely resected, pathologic stage I–IIIA, high-grade neuroendocrine carcinoma of the...
Surgical Technical Skill and Long-Term Survival After Surgery for Colon Cancer
In a study reported as a research letter in JAMA Oncology, Brajcich et al found that higher-rated surgical technical skill was associated with significantly improved long-term survival in patients undergoing surgery for colon cancer. Study Details In the study, surgeons were recruited from the...
Genetic Variants Linked to Bevacizumab-Induced Adverse Effects
Two common genetic variants appear to be linked to toxicity induced by bevacizumab, researchers reported at the 32nd European Organisation for Research and Treatment of Cancer (EORTC)–National Cancer Institute (NCI)–American Association for Cancer Research (AACR) Symposium on Molecular Targets and...
Comanagement of Induction Therapy for Acute Promyelocytic Leukemia by Experts and Community Practices
In a study reported in JCO Oncology Practice, Anand P. Jillella, MD, and colleagues found that physician education on the main causes of death during induction treatment for acute promyelocytic leukemia (APL)—and comanagement of cases with expert physicians—resulted in a low early mortality rate...
Closing the Gap in Integrative Oncology Education
Launched in 2018 at the University of Michigan Medical School in Ann Arbor, the Integrative Oncology Scholars Program has trained 50 oncology professionals in evidence-based complementary therapies in the treatment of patients with cancer. Another 50 trainees are expected to complete the program by ...
James L. Mulshine, MD, on Meeting Highlights: Advancing Quantitative Low-Dose CT Imaging in Thoracic Disease
James L. Mulshine, MD, of Rush University Medical Center, offers an overview of the 2020 Quantitative Imaging Workshop, whose mission is to leverage the use of CT to speed early detection and improve the management of lung cancer and other thoracic diseases.
Rising Tide Foundation for Clinical Cancer Research Career Pathway Grants in Symptom Management
Conquer Cancer, the ASCO Foundation® announced the 2020 recipients of the Conquer Cancer–Rising Tide Foundation for Clinical Cancer Research Career Pathway Grants in Symptom Management. The Career Pathway Grants in Symptom Management are awarded to recruit and retain young physician-scientists...
COVID-19’s Impact on Cancer Care Around the World: Perspectives From the ASCO International Affairs Committee
As the world continues to respond to the COVID-19 pandemic, ASCO is committed to providing the most current information and resources to its members and the larger oncology community to help ensure that patients with cancer receive high-quality care. Here, members of the ASCO International Affairs...
Inaugural Class of FDA-AACR Oncology Educational Fellows Announced
The American Association for Cancer Research (AACR) has announced the 2020–2021 class of U.S. Food and Drug Administration (FDA)-AACR Oncology Educational Fellows. This is the first year of the fellowship, a joint initiative of the Oncology Center of Excellence at the FDA and the AACR. The...
Stereo X-Ray of Stomach Cancer
The text and photograph here are excerpted from a four-volume series of books titled Oncology: Tumors & Treatment, A Photographic History, The X-Ray Era 1901–1915 by Stanley B. Burns, MD, FACS, and Elizabeth A. Burns. Photograph courtesy of Stanley B. Burns, MD, and The Burns Archive. A few...
A Doctor Shares His Rich Life in Medicine and Cancer Research
“What am I doing here? This question kept running through my mind as the incoming freshman medical students at the University of Chicago assembled for the first time.” The person asking the introspective question was Marvin Stone, fresh out of college, recently married to his wife, Jill, and now a...
As a Young Oncologist, Enrique Soto Pérez de Celis, MD, MSc, Met a Career-Changing Mentor at the ASCO Annual Meeting
Geriatric oncologist and researcher Enrique Soto Pérez de Celis, MD, MSc, was born in Mexico City and grew up in the nearby city of Puebla. “There were no physicians in the family who might have influenced my decision to become a doctor, but both of my parents were academics; my mother was a...
Pancreatic Adenocarcinoma: Leveraging Molecular Data to Drive Clinical Advances
With the worst 5-year overall survival of all cancers and the second-leading cause of cancer death, pancreatic adenocarcinoma remains a dismal prognosis for the vast majority of patients. However, more accurate tumor staging and better understanding of distinct molecular subgroups have started to...
Committed to Excellence: Oncology Drug Development Marches on Amid a Pandemic
Instituted as part of the 21st Century Cures Act, the Oncology Center of Excellence (OCE) fosters a unified interaction between three U.S. Food and Drug Administration (FDA) centers: Center for Biologics Evaluation and Research, Center for Drug Evaluation and Research, and Center for Devices and...
Liquid Biopsy: Mounting Evidence Shows Clinical Utility in Tumor Monitoring
A “blood-first” approach could soon shift the diagnostic paradigm in advanced lung cancer, replacing tissue biopsy with minimally invasive assays. According to Natasha B. Leighl, MD, MMSc, FRCPC, FASCO, there is rapidly mounting evidence that liquid biopsy serves a prognostic function in advanced...
After Leaving His Home in Syria to Train Abroad, an Oncologist Makes a Tough Decision to Return
For this installment of the Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with Nedal Estfan, MD, a noted Syrian oncologist who was at the forefront of his county’s earliest efforts to establish a national cancer care system during a time of political and military turmoil....
CURE Media Group Announces Recipients of 2020 Lung Cancer Heroes Award
The CURE Media Group, a multimedia platform devoted to cancer updates and research that reaches more than 1 million patients, recently announced four recipients of the inaugural 2020 Lung Cancer Heroes awards and the recipient of the Lifetime Achievement award. The 2020 Lung Cancer Heroes are:...
Do All Patients With Refractory Diffuse Large B-Cell Lymphoma Need CAR T-Cell Therapy?
Chimeric antigen receptor (CAR) T-cell therapy has made great strides in treating patients with relapsed or refractory diffuse large-B cell lymphoma (DLBCL) and refractory mantle cell lymphoma (MCL), but there may be newer strategies that can produce equivalent outcomes, and not all patients with...
No Biochemical Progression-Free Survival Benefit With Adjuvant vs Salvage Radiotherapy After Radical Prostatectomy for Prostate Cancer
As reported in The Lancet by Christopher C. Parker, MD, of Royal Marsden NHS Foundation Trust, Sutton, United Kingdom, and colleagues, initial findings in the phase III RADICALS-RT trial have shown no biochemical progression-free survival benefit with adjuvant radiotherapy vs a policy of salvage...
Results From ASCO’s 2020 National Cancer Opinions Survey
As in past years, the results from ASCO’s 2020 National Cancer Opinions Survey showed a startling dichotomy in the perceptions of Americans on a variety of health-care issues. As expected, the two major events this year, the COVID-19 pandemic and a national reckoning over racial injustice,...
Lung Cancer: Precision Therapies at the Forefront
What a difference 20 years have made! In the year 2000, the results of the ECOG 1594 trial were reported at the plenary session of the ASCO Annual Meeting. The study demonstrated comparable outcomes between four different platinum-based chemotherapy regimens for the treatment of metastatic...
Surgery Improves Survival in Older Women With Early Estrogen Receptor–Positive Breast Cancer
Older women with estrogen receptor–positive breast cancer have poorer survival than younger women, but this gap might be closed by offering surgery to women over age 70 who are fit and have resectable tumors. According to a study presented at the 12th European Breast Cancer Conference (EBCC 12),...
Expert Point of View: Tim Price, MBBS, DHthSc
The invited discussant of PRODIGE 13 was Tim Price, MBBS, DHthSc, Professor at the University of Adelaide, Australia, senior consultant medical oncologist, and Director of Medical Oncology and Clinical Cancer Research at the Queen Elizabeth Hospital. As he reminded listeners, the current ASCO...
Richard Pazdur, MD, Awarded the Simon M. Shubitz Cancer Prize and Lectureship
For more than 4 decades, the University of Chicago Cancer Research Foundation’s Simon M. Shubitz Cancer Prize and Lectureship has honored an internationally renowned individual for his or her exceptional contributions to cancer research and clinical care. The recipient of this year’s award is...
Expert Point of View: Amy Tiersten, MD and Erika Hamilton, MD
Sharing their thoughts on KEYNOTE-355 were Amy Tiersten, MD, Professor of Medicine at Icahn School of Medicine at Mount Sinai, New York, and Erika Hamilton, MD, Director of the Breast and Gynecologic Research Program at Sarah Cannon Research Institute/Tennessee Oncology, Nashville, who presented...
First-Line Pembrolizumab Delays Disease Progression in PD-L1–Expressing Metastatic Triple-Negative Breast Cancer
In the phase III KEYNOTE-355 trial, pembrolizumab combined with several chemotherapy partners yielded a statistically significant and clinically meaningful improvement in progression-free survival vs chemotherapy alone in patients with previously untreated locally advanced or metastatic...
Jame Abraham, MD, FACP, Named Deputy Editor of JCO Oncology Practice
Jame Abraham, MD, FACP, has been named Deputy Editor of ASCO’s JCO Oncology Practice (JCO OP). Dr. Abraham is Chairman of the Department of Hematology and Medical Oncology at Cleveland Clinic and Professor of Medicine at Cleveland Clinic Lerner College of Medicine. The mission of JCO OP, now in...
David Yankelevitz, MD, on Early-Stage Lung Cancer: Renewed Interest in Combined-Modality Treatment
David Yankelevitz, MD, of the Icahn School of Medicine at Mount Sinai, discusses the renewed interest in applying adjuvant and neoadjuvant targeted treatments to earlier-stage lung cancer, given the promising results in more advanced disease. The challenges, he says, include identifying patient...
Recently Approved and Emerging Therapies for Triple-Negative Breast Cancer
“Triple-negative breast cancer has multiple different subtypes, and there are targeted therapies that can be used based on the biomarkers that we identify for each patient,” Kari B. Wisinski, MD, noted in a review of recently approved and emerging therapies at the 2020 Lynn Sage Breast Cancer...
Cancer in Older Adults: The History of Geriatric Oncology, Part 3
In the preceding two issues of The ASCO Post, we explored the overall history of geriatric oncology from 1980 to 2020. In this concluding part of the series, we focus on the invaluable contributions made by oncology nurses to the field. Over the past several decades, geriatric oncology has...
National Academy of Medicine Elects New Members
The National Academy of Medicine recently announced the election of 90 regular members and 10 international members during its annual meeting. Election to the Academy is considered one of the highest honors in the fields of health and medicine and recognizes individuals who have demonstrated...
Second-Line Pembrolizumab Improves Overall Survival vs Chemotherapy in Patients with Advanced Esophageal Cancer
As reported in the Journal of Clinical Oncology by Takashi Kojima, MD, of the National Cancer Center Hospital East, Kashiwa, Japan, and colleagues, the phase III KEYNOTE-181 trial has shown that second-line pembrolizumab improved overall survival vs the investigator choice of chemotherapy in...
Cancer on the Global Stage: Incidence and Cancer-Related Mortality in Chile
Chile has a population of approximately 19 million living predominantly in urban areas (87.7%), with a population density of 66 inhabitants per square mile.1 For the year 2020, approximately 12% of its population was older than 65 years.1 Socioeconomic Trends and Cancer The country has experienced ...
Fred R. Hirsch, MD, PhD, on Early-Stage Lung Cancer: Targeted Treatment and Screening
Fred R. Hirsch, MD, PhD, of The Tisch Cancer Institute at Mount Sinai, discusses lung cancer screening for aggressive early-stage lung cancer; adjuvant and neoadjuvant treatment, including the ADAURA study of EGFR-positive tumors; and how cell-free DNA analysis might be used in the future to...
Biomarker-Driven Master Protocol to Test Therapies for Previously Treated Patients With Squamous NSCLC
In an article published in The Lancet Oncology, Redman et al described the conduct of and findings from the Lung Cancer Master Protocol (Lung-MAP; SWOG S1400), a completed biomarker-driven master protocol designed to address the need for improved therapies for previously treated patients with...
Study Identifies Genetic Variants Linked to Bevacizumab-Induced Adverse Events
Researchers have found two common genetic variants that may be used to predict whether patients with cancer may have severe adverse events when treated with the anti-VEGF monoclonal antibody bevacizumab. A genome-wide association study—according to researchers, the largest such study in patients...
Potential Factors in Prognostic Discrepancies Among Tests for Recurrence Risk in Patients With Breast Cancer Receiving Endocrine Therapy
The TransATAC study reported by Buus et al in the Journal of Clinical Oncology sought to identify causes of discrepancies among tests for determining the risk of breast cancer recurrence in patients with estrogen receptor–positive, HER2-negative disease receiving endocrine therapy. The...
